| Cat. No. |
Product Name |
Information |
| PC-42040 |
Bay 41-4109
HBV capsid inhibitor
|
Bay 41-4109 is a potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM. |
| PC-23942 |
ALG-001075
HBV capsid modulator
|
ALG-001075 is a potent HBV capsid assembly modulator (CAM), inhibits HBV DNA production with EC50 of 0.63 nM in HepG2.117 cell-based assay. |
| PC-23941 |
ALG-000184
HBV capsid modulator
|
ALG-000184 is a highly soluble prodrug of the potent HBV capsid assembly modulator (CAM) ALG-001075 (HepG2.117, EC50=0.63 nM). |
| PC-23940 |
HBV RNaseH inhibitor 1466
HBV RNaseH inhibitor
|
HBV RNaseH inhibitor 1466 is a small molecule inhibitor of HBV RNaseH, inhibits HBV replication with EC50 of 0.25 uM, decreases capsid and core protein accumulation in HepDES19 and HepG2.2.15 cells. |
| PC-23459 |
AB-161
PAPD5/7 inhibitor
|
AB-161 is a potent, selective and orally bioavailable PAPD5/7 inhibitor (IC50=0.85/1.1 uM) and HBV RNA destabilizer with EC50 of 2.2 nM for reduction of HBsAg in HepG2.2.15 cells. |
| PC-22187 |
GS-6671
HBsAg inhibitor
|
GS-6671 is a potent, orally bioavailable inhibitor of HBV surface antigen (HBsAg) with EC50 of 5.8 nM in HepG2-NTCP assays, via inhibition of the human poly(A) polymerases PAPD5/7, promoting destabilization and degradation of HBV mRNA. |
| PC-22186 |
GS-8873
HBsAg inhibitor
|
GS-8873 is a potent, orally bioavailable inhibitor of HBV surface antigen (HBsAg) with EC50 of 4 nM in HepG2-NTCP assays, via inhibition of the human poly(A) polymerases PAPD5/7, promoting destabilization and degradation of HBV mRNA. |
| PC-21261 |
Alisporivir
Cyclophilin inhibitor
|
Alisporivir (Debio 025, DEBIO-025) is a non-immunosuppressive cyclophilin inhibitor derived from cyclosporin A (CsA) with IC50 of 30 nM (CypD PPIase activity ), inhibits HCV replication in vitro more potently than CsA. |
